一个患有急性淋巴细胞白血病的儿童的慢性药物诱导肝损伤:一个病例报告
Shi-Qiu Xiong1, Ku-Ku Ge1, Yan-Fei Liu2
1Gastroenterology, Xi'an Children's Hospital, Xi 'an, Shaanxi, 710008, China.
BMC pediatrics
|November 22, 2025
概括
儿科急性淋巴细胞白血病 (ALL) 患有复发性药物诱导性肝损伤 (DILI) 的患者可以发展慢性DILI,导致肝硬化和门性高血压. 长期监测对于早期发现和管理这种罕见并发症至关重要.
科学领域:
- 儿科血液学 瘤学 儿科血液学
- 肝病学 肝病学是一种肝病学.
- 临床案例研究 临床案例研究
背景情况:
- 急性淋巴细胞白血病 (ALL) 是一种常见的儿童癌症,需要密集化疗.
- 对ALL的化疗可以诱导药物诱导性肝损伤 (DILI),这是一个重大的临床挑战.
- 慢性DILI可以发展为严重的肝病,包括肝硬化和门性高血压.
研究的目的:
- 报告一种罕见的慢性药物诱导性肝损伤 (DILI) 在患有急性淋巴细胞白血病 (ALL) 的儿科患者中进展的罕见病例.
- 为了突出肝硬化和门高血压的发展二级DILI在儿科ALL幸存者.
- 强调需要对所有有DILI病史的患者进行警的长期监测.
主要方法:
- 一份病例报告详细介绍了一名14岁的男孩,他有ALL病史和复发性DILI.
- 临床表现包括严重的胃肠道出血,肝酶升高和贫血.
- 诊断工作包括实验室检测,成像 (超声波,CT),肝脏活检和食道胃二透镜.
主要成果:
- 患者出现了食道和胃的静脉动脉,这表明了门门高血压.
- 肝活检证实肝硬化,归因于慢性DILI.
- 患者经历了成功的食道水绑定.
结论:
- 儿科ALL患者的复发性DILI存在患慢性肝病的风险.
- 长期的临床,生化和放射性随访对所有DILI患者至关重要.
- 在化疗期间和之后,应继续进行监测,以检测慢性DILI的进展.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
170
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
170
Pharmacokinetics in Pediatric Patients: Drug Excretion
196
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
196
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
204
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
204
Pharmacokinetics in Pediatric Patients: Drug Metabolism
179
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
179


